Reply to Office Action of March 15, 2010

REMARKS

The sole basis for rejection in the outstanding Office action relates to alleged

scope of enabling disclosure. The Office acknowledges, at page 3 of the action, enablement

relating to determining presence or risk of breast cancer by evaluating a patient sample for

increased expression of the gene at issue in the sample compared to normal control breast

tissue.

Although the application is enabling for additional embodiments of the

invention, to expedite allowance the Applicants have amended the claims to be

commensurate in scope with the invention that the Office has acknowledged to be enabled.

Accordingly, the rejection is moot, and should be withdrawn.

The amendment to claim 5 finds support throughout the application, including

at page 8, lines 28-31.

In view of the foregoing the application is believed to be in condition for

By_

allowance.

Dated: June 14, 2010

Respectfully submitted,

David A. Gass

Registration No.: 38,153

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive 6300 Willis Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant

4